10:54 AM EDT, 08/21/2025 (MT Newswires) -- Telix Pharmaceuticals' ( TLX ) profitability is expected to rebound amid its continued integration with RLS and the commercial launch of Gozellix, Wedbush said in a note Thursday following Telix's H1 results.

The company reported late Wednesday H1 operating profit of $10.4 million, down from $27.7 million a year earlier.

Wedbush analysts said that Telix's gross margin saw some pressure due to the RLS acquisition, but margins for Telix's prostate cancer PET imaging agent Illuccix stayed steady at 64% in H1.

Also, Illuccix keeps increasing its market share, with US volumes up 7% quarter on quarter, the investment firm said. Meanwhile, Illuccix may see incremental growth from regulatory milestones like getting reimbursement in more markets in Europe and from a potential Chinese marketing approval next year, the note said.

Wedbush reiterated an outperform rating on the stock with a $22 price target.

Shares were up 10% in recent trading.

Price: 12.07, Change: +1.10, Percent Change: +10.03